CA2195668A1 - Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression - Google Patents

Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression

Info

Publication number
CA2195668A1
CA2195668A1 CA002195668A CA2195668A CA2195668A1 CA 2195668 A1 CA2195668 A1 CA 2195668A1 CA 002195668 A CA002195668 A CA 002195668A CA 2195668 A CA2195668 A CA 2195668A CA 2195668 A1 CA2195668 A1 CA 2195668A1
Authority
CA
Canada
Prior art keywords
regulation
heavy chain
mhc class
human cytomegalovirus
identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002195668A
Other languages
French (fr)
Other versions
CA2195668C (en
Inventor
Ann E. Campbell
Thomas R. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Eastern Virginia Medical School
Original Assignee
Ann E. Campbell
Thomas R. Jones
American Cyanamid Company
Eastern Virginia Medical School Of The Medical College Of Hampton Roads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ann E. Campbell, Thomas R. Jones, American Cyanamid Company, Eastern Virginia Medical School Of The Medical College Of Hampton Roads filed Critical Ann E. Campbell
Publication of CA2195668A1 publication Critical patent/CA2195668A1/en
Application granted granted Critical
Publication of CA2195668C publication Critical patent/CA2195668C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/03Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04Varicella-zoster virus
    • C07K14/045Cytomegalovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161Methods of inactivation or attenuation
    • C12N2710/16162Methods of inactivation or attenuation by genetic engineering

Abstract

Infection of human fibroblast cells with human cytomegalovirus (HCMV) causes down-regulation of cell surface expression of MHC
class I. The present invention is directed to a mutant with a 9-kb deletion in the S component of the HCMV genome (including open reading frames IRS1-US9 and US11) which fails to down-regulate class I heavy chains. By examining the phenotypes of mutants with smaller deletions with this portion of the HCMV genome, a 7-kb region containing at least 9 open reading frames was shown to contain the genes required for reduction in heavy chain expression. Furthermore, it was determined that two subregions (A and B) of the 7-kb region each contained genes which were sufficient to cause heavy chain down-regulation. In subregion B, the US11 gene product is involved.
It encodes an endoglycosidase H-sensitive glycoprotein which is intracytoplasmic, similar to the adenovirus type 2 E3-19K glycoprotein which inhibits surface expression of class I heavy chains.
CA002195668A 1994-07-29 1995-07-28 Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression Expired - Fee Related CA2195668C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/282,696 US5846806A (en) 1994-07-29 1994-07-29 Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
US08/282,696 1994-07-29
PCT/US1995/009607 WO1996004383A1 (en) 1994-07-29 1995-07-28 Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression

Publications (2)

Publication Number Publication Date
CA2195668A1 true CA2195668A1 (en) 1996-02-15
CA2195668C CA2195668C (en) 2004-09-21

Family

ID=23082718

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002195668A Expired - Fee Related CA2195668C (en) 1994-07-29 1995-07-28 Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression
CA002328638A Abandoned CA2328638A1 (en) 1994-07-29 1995-07-31 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression
CA002196207A Expired - Fee Related CA2196207C (en) 1994-07-29 1995-07-31 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA002328638A Abandoned CA2328638A1 (en) 1994-07-29 1995-07-31 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression
CA002196207A Expired - Fee Related CA2196207C (en) 1994-07-29 1995-07-31 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression

Country Status (11)

Country Link
US (6) US5846806A (en)
EP (2) EP0775209A1 (en)
JP (2) JP4036469B2 (en)
KR (2) KR970704884A (en)
AU (2) AU709552B2 (en)
CA (3) CA2195668C (en)
FI (2) FI970352A (en)
MX (1) MX9700676A (en)
NO (2) NO970369L (en)
NZ (2) NZ290718A (en)
WO (2) WO1996004383A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032605A1 (en) * 1996-03-08 1997-09-12 Massachusetts Institute Of Technology Cytomegalovirus nucleic acids encoding proteins having normal or altered class i mhc binding and treatment of diseases
PT966301E (en) * 1996-07-31 2005-06-30 Ortho Mcneil Pharm Inc IDENTIFICATION OF HUMAN CITOMEGALOVIRUS GENES INVOLVED IN THE NEGATIVE ADJUSTMENT OF MHC HEAVY CHAIN EXPRESSION CLASS I
WO1998031813A1 (en) * 1997-01-17 1998-07-23 Roche Diagnostics Gmbh Inhibitors of antigen presentation by mhc class i molecules
WO1998047914A2 (en) * 1997-04-18 1998-10-29 Roche Diagnostics Gmbh Us6 gene from the human cytomegalovirus (hcmv)
EP1045920A1 (en) * 1998-01-14 2000-10-25 Human Gene Therapy Research Institute Nucleotide expression systems with reduced immunogenicity for use in gene therapy
US6100008A (en) * 1998-09-14 2000-08-08 Ppg Industries Ohio, Inc. Positive photoresist with improved contrast ratio and photospeed
WO2000046361A1 (en) * 1999-02-02 2000-08-10 Oregon Health Sciences University Inhibition of the mhc class ii antigen presentation pathway and presentation to cd4+ cells
WO2002018954A2 (en) 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US20030118568A1 (en) * 2001-12-18 2003-06-26 Board Of Trustees Of The University Of Arkansas Viral stealth technology to prevent T cell-mediated rejection of xenografts
US20040228842A1 (en) * 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
KR20050093003A (en) * 2004-03-17 2005-09-23 이재본 Micro turbine generator
JP2010517544A (en) 2007-02-07 2010-05-27 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ Recombinant antigen of human cytomegalovirus (HCMV)
WO2009073330A2 (en) * 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
CA2793959C (en) * 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT2772265T (en) 2010-05-14 2018-04-20 Univ Oregon Health & Science Recombinant hcmv and rhcmv vectors and uses thereof
AU2012267786B2 (en) 2011-06-10 2017-08-03 Oregon Health & Science University CMV glycoproteins and recombinant vectors
WO2014138209A1 (en) 2013-03-05 2014-09-12 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting
MA39818A (en) 2014-03-30 2017-02-08 Benevir Biopharm Inc Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof
BR112017000696B1 (en) 2014-07-16 2023-10-03 Oregon Health & Science University ISOLATED POLYNUCLEOTIDE
CN114317611A (en) * 2015-02-10 2022-04-12 俄勒冈健康与科学大学 Methods and compositions useful for generating atypical CD8+ T cell responses
US10688164B2 (en) 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CA3028827A1 (en) 2016-06-22 2017-12-28 Aeras Recombinant cytomegalovirus vectors as vaccines for tuberculosis
JP2019531745A (en) 2016-10-18 2019-11-07 オレゴン ヘルス アンド サイエンス ユニバーシティ Cytomegalovirus vector that induces T cells restricted by major histocompatibility complex E molecules
EP3697806A4 (en) 2017-10-17 2021-10-27 International AIDS Vaccine Initiative, Inc. Tuberculosis antigen cassettes
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058598A (en) * 1974-10-18 1977-11-15 Harold Stern Cytomegalovirus attenuation method and vaccine
US4689225A (en) * 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US4877612A (en) * 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
US4877737A (en) * 1985-09-06 1989-10-31 Prutech Research And Development Partnership Attenuated pseudorabies virus which has a deletion in at least a portion of a repeat sequence and vaccine containing same
US5273876A (en) * 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
WO1988010311A1 (en) * 1987-06-26 1988-12-29 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene and use thereof
AU3550489A (en) * 1988-05-09 1989-11-29 Children's Hospital Incorporated, The Vectors encoding hcmv glycoprotein and expression products
SG49046A1 (en) * 1991-07-05 1998-05-18 American Cyanamid Co Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus

Also Published As

Publication number Publication date
JPH10506268A (en) 1998-06-23
WO1996004383A1 (en) 1996-02-15
NO970370D0 (en) 1997-01-28
NO970369D0 (en) 1997-01-28
AU709552B2 (en) 1999-09-02
AU3153595A (en) 1996-03-04
CA2195668C (en) 2004-09-21
CA2196207A1 (en) 1996-02-15
FI970352A0 (en) 1997-01-28
US5846806A (en) 1998-12-08
AU3274595A (en) 1996-03-04
JP4036469B2 (en) 2008-01-23
NO970369L (en) 1997-03-21
EP0772681A1 (en) 1997-05-14
KR970704883A (en) 1997-09-06
CA2196207C (en) 2002-04-30
KR970704884A (en) 1997-09-06
US5753476A (en) 1998-05-19
FI970352A (en) 1997-01-28
NZ290718A (en) 1999-03-29
US5843458A (en) 1998-12-01
US5906935A (en) 1999-05-25
MX9700710A (en) 1997-09-30
NO970370L (en) 1997-03-24
FI970351A (en) 1997-01-28
US5908780A (en) 1999-06-01
JPH10503378A (en) 1998-03-31
AU708983B2 (en) 1999-08-19
NZ291571A (en) 1999-01-28
CA2328638A1 (en) 1996-02-15
MX9700676A (en) 1997-04-30
US5720957A (en) 1998-02-24
EP0775209A1 (en) 1997-05-28
FI970351A0 (en) 1997-01-28
WO1996004384A1 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
CA2195668A1 (en) Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression
ATE396274T1 (en) HERPES SIMPLEX VIRUS STRAINS
AU2853395A (en) Recombinant vectors derived from adenovirus for use in gene therapy
GR3021426T3 (en) Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
GB2234972B (en) Herpes simplex virus type 1 mutant
WO1995027071A3 (en) An adenovirus supervector system
AU3498989A (en) Non-linear genetic algorithms for solving problems
AU585126B2 (en) Recombinant herpes simplex viruses, vaccines and methods
IL113955A0 (en) The cytoplasmic inhibition of gene expression
AU8221191A (en) Probes for detecting mutant p53
WO1992017152A3 (en) Method for detecting and treating alzheimer's disease
NZ334147A (en) Immortalised cell lines derived from chicken embryonic fibroblasts and having a population doubling rate of 0.6 to 1.2 population doublings per day
CA2146734A1 (en) Method for long term subculture of dermal papilla cells
FI963924A0 (en) Gene that gives the yeast the ability to flocculate and gene product
AU5787490A (en) Process for reducing the crystal size of ondanestron hydrochloride dihydrate
CA2095109A1 (en) Process for production of exogenous gene or its product in plant cells
GB2359083A (en) Mutant herpes simplex viruses and uses thereof
WO1999060138A3 (en) Regulated expression of pkc and/or srb1/psa1 in yeast
ATE190663T1 (en) CD69 - TRANSCRIPTION REGULATORY ELEMENTS
EP1566444A3 (en) Yield-related genes
Zhou et al. Development and Improvement of SY High-Rigid Rolling Mill
EP0828005A3 (en) Apoptotic agents for tumor cells of the nervous system
AU3512793A (en) Process for the expression of herpes simplex virus type 1 glycoprotein I and methods of use
STRAIN THE FOLLOWING articles have been accepted for publication in Experimental Gerontology and will appear in forthcoming issues of this journal.
AU4943296A (en) Leveller bar for coke ovens

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed